HMGB2 and triple-A syndrome: Moreover,these authors reported that a potential therapeutic strategy for AAA may be theinhibition of HMGB2-regulated ferroptosis and inflammation inangiotensin-II-treated VSMCs through inactivation of NF-κβsignaling.